|Bid||309.61 x 900|
|Ask||309.70 x 900|
|Day's Range||307.17 - 312.45|
|52 Week Range||263.30 - 380.76|
|Beta (3Y Monthly)||1.31|
|PE Ratio (TTM)||49.13|
|Earnings Date||Oct 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||329.25|
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
For more than a decade now genomic medicine has been revolutionizing the way we diagnose and treat disease. Illumina (ILMN) has been at the forefront of that revolution, notes growth stock expert Ian Wyatt, editor of Million Dollar Portfolio.
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 28. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
Illumina, Inc. (ILMN) today announced that it will issue results for third quarter 2019 following the close of market on Thursday, October 24, 2019. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, October 24, 2019.
Qiagen NV (NYSE: QGEN) shares were coming under intense selling pressure Tuesday following a trio of announcements from the company. The German molecular and genetic testing company announced preliminary third-quarter results and said it expects net sales growth of 3% at constant exchange rates, lower than its previous outlook for 4-5% CER growth. Qiagen attributed the weakness to significantly weaker-than-expected developments in China.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 7) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Celgene ...
Illumina, Inc. (ILMN) and QIAGEN N.V. (QGEN) (Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based IVD kits, including companion diagnostics, for patient management. The agreement grants QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina’s MiSeq™ Dx and NextSeq™ 550Dx Systems. The agreement also includes rights for expansion of the partnership on future Illumina diagnostic (Dx) systems.
The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Illumina, Inc. (ILMN) and the Broad Institute of MIT and Harvard today announced they have entered into a collaboration for the co-development of secondary genomic analysis algorithms and software. Top data scientists from both institutions will collaborate to bring together the industry-leading open-source GATK algorithms with the speed and enhanced accuracy of Illumina’s DRAGEN™ (Dynamic Read Analysis for GENomics) Bio-IT Platform for commonly used methods, including small variant (SNV) and large variant (CNV/SV) detection.
Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a partnership with Illumina, Inc. (ILMN) to develop in-vitro diagnostic (IVD) test kits for Adaptive’s current and future portfolio of next-generation sequencing (NGS)-based immunodiagnostics. The test kits under development would expand the availability of Adaptive’s clonoSEQ® Assay for assessing and monitoring minimal residual disease (MRD) for the management of patients with certain blood cancers and immunoSEQ Dx™ Assay for pipeline applications.
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
Illumina, Inc. (ILMN) today announced the appointment of Joydeep Goswami as Senior Vice President of Corporate Development and Strategic Planning. Mr. Goswami will be responsible for driving planning, strategic partnerships and acquisitions, and will report to President and Chief Executive Officer, Francis deSouza. With more than 20 years of global experience, Mr. Goswami has a strong track record of developing strategy and leading new product development, partnerships, licensing, and mergers and acquisitions.